Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The University of Oxford leads the world in Clinical, Pre-Clinical and Health subjects, for the third consecutive year, in the Times Higher Education World University Rankings subject tables.

Universities from across the world are judged on 13 criteria measuring teaching, research, knowledge transfer and international outlook, providing a balanced and trusted comparison of universities.

As the THE notes today, the university’s Medical Sciences Division is one of the largest biomedical research centres in Europe. It has one of the largest clinical trial portfolios in the UK and specialises in taking discoveries from the lab bench to the clinic. Its partnerships with local NHS trusts enable patients to benefit from close links between medical research and delivery.  Additionally, through its network of clinical research units in Asia and Africa, the university’s medical researchers are leading the fight against the world’s most pressing health challenges, including the resurgence of tuberculosis, mutating influenza viruses and HIV/Aids.  This builds on its already impressive historical record; medical scientists at Oxford have, among many achievements, led the development of penicillin, laid the groundwork for immunisation by discovering how antibodies and the immune system work and have also provided incontrovertible evidence for the link between smoking and cancer.

Dean of the Medical School and Head of the Medical Sciences Division, Professor Alastair Buchan, said: ‘We are delighted that once again Oxford University is ranked best in the world for medicine. It’s the third year in a row that we’ve sat on top of the table. It’s testament to the efforts of all those involved in medicine at Oxford, our researchers, our students and our staff. With such people and the truly fantastic facilities we have here, Oxford really is leading the world in advancing our understanding of humans in health and disease and training the next generation of leading scientists, researchers and clinicians.’

Furthermore, the University took joint second place, tied with Harvard University, in the overall Top 100 university rankings. 

Related news:

Oxford top UK university

Similar stories

£100 million donation from Ineos to create new institute to fight antimicrobial resistance

Awards and Appointments General Innovation

A new state of the art institute for antimicrobial research is to open at Oxford University thanks to a £100 million donation from Ineos.

MRC HIU appoints new Director

Awards and Appointments General

We are pleased to announce that Professor Alison Simmons has been appointed as the new Director of the MRC Human Immunology Unit.

New Year's Honours 2021

Awards and Appointments General

Members of the Medical Sciences Division have been recognised in the New Year's Honours list for 2021.

Oxford University awarded £2.4 million to fund DPhil research in inflammation, immunology and musculoskeletal disease

Awards and Appointments General

Oxford University has been awarded a £2.4 million grant, as part of the Kennedy Trust MB PhD scheme, to fund undergraduate medical students to undertake DPhil research in the areas of inflammation, immunology and musculoskeletal disease.

Professor Sir Rory Collins awarded the MRC Millennium Medal 2020

Awards and Appointments General

Professor Sir Rory Collins, Head of the Nuffield Department of Population Health, and Principal Investigator and Chief Executive of UK Biobank, has been awarded the Medical Research Council (MRC) Millennium Medal 2020, the MRC’s most prestigious personal award.

University spinout PepGen awarded major financing to target Duchenne muscular dystrophy

Awards and Appointments General Innovation

PepGen, a therapeutics company targeting severe neuromuscular diseases, including Duchenne muscular dystrophy (DMD), has closed a $45 million Series A funding round led by RA Capital Management with participation from Oxford Sciences Innovation (OSI), the company’s original seed investor.